ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
-0.10%
US Dollar vs MXN
16.70624
0.15%
Brent Oil
83.535
0.40%
Bitcoin
65,656.50
0.64%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) Noticias

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:AZN
FechaHoraFuenteTítuloSímboloCompañía
01/11/202314:15AllPennyStocks.comBiotech Shares Soar After AstraZeneca Stake & Research CollaborationNYSE:AZNAstraZeneca PLC
28/06/202316:28Edgar (US Regulatory)Annual Report of Employee Stock Plans (11-k)NYSE:AZNAstraZeneca PLC
02/06/202311:13Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NYSE:AZNAstraZeneca PLC
13/03/202315:38Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)NYSE:AZNAstraZeneca PLC
02/03/202315:55Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NYSE:AZNAstraZeneca PLC
01/03/202305:27Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NYSE:AZNAstraZeneca PLC
24/01/202312:59Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:AZNAstraZeneca PLC
11/11/202205:43TipRanksFDA Approves AstraZeneca’s (NASDAQ:AZN) Lung Cancer Combination TreatmentNYSE:AZNAstraZeneca PLC
10/11/202207:06TipRanksAstraZeneca (NASDAQ:AZN) Stock Rises on Upbeat Q3 Results, Guidance LiftNYSE:AZNAstraZeneca PLC
01/11/202204:08TipRanksAstraZeneca’s COVID-19 Vaccine Granted Full Approval in EUNYSE:AZNAstraZeneca PLC
16/09/202206:30TipRanksAstraZeneca (NASDAQ: AZN) Up on Positive Clinical Data and Evusheld ApprovalNYSE:AZNAstraZeneca PLC
08/07/202215:58Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:AZNAstraZeneca PLC
05/07/202208:31TipRanksHere’s How AstraZeneca Is Gearing up against LymphomaNYSE:AZNAstraZeneca PLC
27/06/202211:26TipRanksAstraZeneca’s Enhertu Wins Approval in EU by CHMPNYSE:AZNAstraZeneca PLC
10/06/202215:11Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NYSE:AZNAstraZeneca PLC
06/06/202202:50TipRanksAstraZeneca Breast Cancer Drug Shows Positive ResultsNYSE:AZNAstraZeneca PLC
04/05/202207:41TipRanksAstraZeneca (AZN) Receives a Buy from SVB SecuritiesNYSE:AZNAstraZeneca PLC
29/04/202222:49TipRanksAstraZeneca (AZN) Receives a Buy from Leerink PartnersNYSE:AZNAstraZeneca PLC
20/04/202217:12Business WireEVUSHELD™  significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populationsNYSE:AZNAstraZeneca PLC
19/04/202206:03TipRanksAstrazeneca, Amoy Diagnostics to Develop Diagnostics ProgramsNYSE:AZNAstraZeneca PLC
06/04/202206:00Business WireULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeksNYSE:AZNAstraZeneca PLC
24/03/202206:00Business WireAstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million TreesNYSE:AZNAstraZeneca PLC
21/03/202206:00Business WireEVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studiesNYSE:AZNAstraZeneca PLC
03/03/202201:56TipRanksAstraZeneca Acquires Neurimmune’s Heart Failure Drug CandidateNYSE:AZNAstraZeneca PLC
22/02/202216:43Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NYSE:AZNAstraZeneca PLC
22/02/202216:19Edgar (US Regulatory)Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)NYSE:AZNAstraZeneca PLC
21/02/202210:15Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast CancerNYSE:AZNAstraZeneca PLC
14/02/202216:00Business WireLYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate CancerNYSE:AZNAstraZeneca PLC
04/02/202208:08Edgar (US Regulatory)Schedule 13gNYSE:AZNAstraZeneca PLC
25/01/202204:27TipRanksAstraZeneca Announces Orphan Drug Designation for Eplontersen in the U.S.NYSE:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NYSE:AZN

Su Consulta Reciente

USOTC
GWTI
Greenway Technologies (QB)
BIT
UB8919
Unicredit Bank
BIT
UB591G
Unicredit Bank
COIN
SONGUSD
NASDAQ
ONYXU
Onyx Acquisition Company I
NASDAQI
BSJM
Invesco BulletShares 202...
ASX
PMP
Pmp
NASDAQ
DUETU
DUET Acquisition
COIN
SXPUST
Swipe
BIT
UB7HNM
Unicredit Bank
LSE
BUL
NASDAQ
AAYFZXX
Bank of Montreal Autocal...
USOTC
VIAAY
Vienna International Air... (PK)
NYSE
HZAC
Horizon Acquisition
ASX
YTMWE2
Equity Trustees
BIT
F33889
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados